African Trials Moving Ahead with Great Success
Our vaccine is currently being tested for safety, tolerability and efficacy in Mali (West Africa) and Tanzania (East Africa).
In memoriam: Donald ‘DA’ Henderson
Sanaria joins the international public health community in remembering Donald 'DA' Henderson after his death on August 19, 2016. Sanaria was honored to receive a visit from DA in June 2011, where after describing his relentless dedication to the eradication of Smallpox, he offered insights, advice and encouragement to Sanaria at what was a critical time in our PfSPZ Vaccine clinical development program.
Weill Cornell Alumni Association Honors Dr. Stephen Hoffman
This year, Dr. Stephen Hoffman, M.D. ’75 was awarded the Weill Cornell Medicine Alumni Association Award of Distinction for his significant accomplishments as a physician, scientist and entrepreneur. Watch:
Sanaria Earns ‘Bioscience Company Of The Year’ Award
The Montgomery County Small Business Awards were announced June 24 and the winner of the "Bioscience Company of the Year" is Sanaria, Inc.
Dr. Stephen L. Hoffman wins 2015 CEO of the year at the World Vaccine Congress, Vaccine Industry Excellence Awards
Announced at the award ceremony during the 15th World Vaccine Congress, the 8th Vaccine Industry Excellence (ViE) Awards recognise those who have done outstanding work in the field, honour those who have made significant contributions to the development of the sector, and celebrate the great achievements made in the world of vaccines in the last year.
Sanaria recognized as a NIH SBIR/STTR Notable Success
“NIH SBIR funding provided Sanaria with critical early-stage dollars to get our lead vaccine off the ground. Without this funding, Sanaria would have never gotten started and our malaria vaccine would not exist. No other investor would have provided money for this type of high-risk research.”
– Dr. Steve Hoffman, CEO of Sanaria
Read the full NIH SBIR story!|
First controlled human malaria infection in Africa shows that PfSPZ Challenge can be used for drug and vaccine development in the field
The innovative PfSPZ Challenge is key to success for speedier testing of new malaria vaccine and drugs.
Minister of Health and Social Welfare Discusses Malaria Vaccine Clinical Trial
In an interview, Equatorial Guinea’s Minister of Health and Social Welfare, Diosdado Vicente Nsue Milang, talks about the government’s partnership with American biotechnology company, Sanaria in conducting a malaria vaccine clinical trial.
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2013
600 participated in fifth annual Frontiers in Science and Medicine Day.
Malaria specialists meeting in Durban
The Minister of Health, together with the heads of the various departments of the ministry and the institutions collaborating in the fight against the disease in Equatorial Guinea, attended the Sixth Pan-African Malaria Conference, held in Durban (South Africa).
Sanaria CEO, Dr. Stephen L. Hoffman answers questions about the SANARIA PfSPZ Vaccine on Reddit’s AMA
Update: The Reddit AMA is now closed but you can go back and read it in the archive.
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2011
Watch the great video!
Sanaria announces the launch of its Sanaria® Family of Products and Services
Sanaria announces the launch of its Sanaria® Family of Products and Services intended to advance research towards new malaria vaccines, drugs, and diagnostics, and enhanced understanding of malaria pathology and immunobiology.
Peter F. Billingsley PhD, Senior Director of Entomology and Quality Systems, joins Editorial Board of the Malaria Journal
Dr. Billingsley joins a distinguished group of malariologists, in recognition of more than 20 years experience in medical entomology and malaria research. Peter has previously served on the editorial boards of major parasitology and entomology journals, the College of Experts for the Medical Research Council (UK), and advisory boards for mosquito control trials in Africa.
Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria’s PfSPZ vaccine
Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria's PfSPZ vaccine.
Dr. David Dolberg, Sanaria’s Director of Intellectual Property, is recognized for his contributions to paradigm changing research in cancer
Sanaria Inc. is proud to recognize and celebrate the role of Dr. David Dolberg, Esq. ‐ Sanaria’s intellectual property attorney ‐ in helping to shape current approaches to the understanding and treatment of cancer. Prior to launching a career in law, David was a postdoctoral fellow in the laboratory of Dr. Mina Bissell at Berkeley, who was recently highlighted in a New York Times article by Gina Kolata, “Old Ideas Spur New Approaches in Cancer Fight” (December 29, 2009).
Adel A. F. Mahmoud, M.D., Ph.D joins Sanaria Board of Directors
Sanaria is pleased to announce that Adel A. F. Mahmoud, M.D., Ph.D, of the Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University and former President of Merck Vaccines, was elected to Sanaria's Board of Directors.
Sanaria CEO Hoffman Most Cited Author in the World
Essential Scientific Indicators has reported that Dr. Stephen L. Hoffman, Founder and Chief Executive Officer of Sanaria Inc., is the most cited author in the world for scientific papers on malaria published between 1995 and 2005.
